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Objective: Statins are reported to have a potential benefit on progression of osteoarthritis 
(OA) and on disease activity in rheumatoid arthritis (RA), but existing evidence is conflicting. 
Our objective was to examine whether statins associate with reduction of joint replacement 
due to OA and RA.
Methods: A propensity score matched cohort study. Settings: Electronic health records from 
the UK Clinical Practice Research Datalink. Participants: We selected people prescribed 
statins and people never prescribed statins. Each statin-user was matched to a non-user by 
age, gender, practice and propensity score for statin prescription. Main outcome measures: 
knee or hip joint replacement overall, and specifically because of OA or RA. Measurements: 
The association between statins and risk of joint replacement was assessed using Cox 
proportional hazard regression. Statin exposure was categorised according to the potency of 
reducing LDL as low (21-28%) medium (32-38%) or high (42-55%) intensity.
Results: 178,467 statin-users were matched with 178,467 non-users by age, gender, practice 
and propensity score. Overall, statin  was not associated with reduced risk of knee or hip 
replacement (HR 0.99, 95% CI 0.97 to 1.03), unless prescribed at high strength (0.86, 0.75 to 
0.98). The reduced risk was only observ d for joint replacement due to RA (0.77, 0.63 to 0.94) 
but not OA (0.97, 0.94 to 1.01).    
Conclusion: Statins at high intensity may reduce the risk of hip or knee replacement.  This 
effect may be RA specific. Further studies to investigate mechanisms of risk reduction and the 
impact in people with RA are warranted.
































































 Statins are routinely used to treat cardiovascular diseases, but also might benefit other 
conditions.
 In this study high dose statins reduced risk of total joint replacement, particularly in RA. 
 Further studies to investigate mechanisms of risk reduction in people with RA are 
warranted.
Introduction
Joint replacement is one of the major economic burdens for healthcare systems worldwide(1-
3). The number of joint replacements performed each year have risen dramatically(4, 5) and 
are set to continue rising with the aging population(6). Waiting-list audits demonstrate that 
current surgical provision does not meet healthcare needs(7). Approximately 90% of all joint 
replacements are performed for osteoarthritis (OA)(6). 
Statins are lipid-lowering drugs recommended for primary and secondary prevention of 
cardiovascular disease (CVD)(8). Statins lower circulating levels of low-density lipoproteins, 
and have other anti-inflammatory and immune-modulating effects(9-14) that have prompted 
studies to examine the potential role of statins as structure-modifying treatments for OA(15). 
Statin use has been associated with an increased risk of development, but not progression, of 
radiographic hip OA in elderly women (16), and with increased risk of progression of 
radiographic knee OA (17, 18). Conversely, one study has reported a protective effect of 
statins on development of knee OA in people with existing CVD (19). However, some more 
recent large studies have not confirmed these findings (20, 21). In the Osteoarthritis Initiative 
cohort statin use was not associated with lower risk of pain worsening, incident radiographic 
knee OA or radiographic symptomatic knee OA unless taken for more than 5 years (22). A 
recent study in the Clinical Practice Research Datalink (CPRD) found that statin therapy 
initiated up to 5 years following total hip/knee replacement may reduce the risk of revision 
arthroplasty(23).  Taking into account existing evidence, the possible effect of statins on 
development and progression of OA remains unclear. 
In contrast, more evidence supports a potential benefit of statins on disease activity, 
attributable to their anti-inflammatory and immunomodulatory properties in rheumatoid arthritis 
(RA)(24-27). For example, a recent meta-analysis of nine randomized controlled  trials found 
that statin use is associated with significantly decreased C-Reactive protein and improved 
disease activity score in patients with RA taking atorvastatin for 12 weeks (28). However, a 
cohort study using the UK primary care database – the QResearch database did not find any 































































benefit of statins on the incidence of RA (29). Whether statins have different effects on joint 
replacements due to OA and RA has not been examined. 
We therefore undertook the present study using a large UK-wide national primary care 
database to investigate the association between statins and risk of joint replacement due to  
OA and RA. 
Methods
Study design
This was a propensity score matched cohort study.
Participants
The CPRD is a large, longitudinal population-based, primary care database that includes data 
on demographics, symptoms, tests, diagnoses, prescriptions and referrals to secondary care 
routinely collected by UK general practitioners (GPs). By July 2017, it covered 718 GP 
practices in England, Scotland, Wales, and Northern Ireland with anonymised health data on 
over 17 million people (26% of the total UK population)(30). The accuracy and completeness 
of the CPRD has been validated by previous studies(31) and many studies have investigated 
effects of statin on various conditions(29, 32-34). We used a fully anonymised data set from 
the General Practice Research Database. We did not obtain participant's consent because 
the participant data were taken from the fully anonymised data set and no participant's identity 
details were revealed. There was no need for participant consent. This study was approved 
by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare 
Products Regulatory Agency (MHRA) database research (protocol 12_020R2AR).
We identified a cohort of patients aged 40 and over, registered with up-to-standard GP 
practices (i.e. practices that met standardised quality criteria based on the continuity of 
recording and the number of recorded deaths) for more than 12 months from 1 January 1987 
to 31 July 2017. Statin-users were defined as people who were ever prescribed a statin (two 
or more prescriptions).   Non-users were defined as people who had never been prescribed 
statins during the period of current registration.
For statin users the index date was defined as the date of first statin prescription. Non-users 
were assigned an index date of their matched statin-users (pairs were matched by year of 
birth, gender and practice). Patients were followed up from the index date until first joint 
replacement, death, deregistration, or end of follow-up (31 July 2017) whichever came first. 
A flow chart of the selected main cohort included is shown in Figure 1. The main cohort was 
further refined for a cohort excluding those with existing cardiovascular disease (CVD) in order 































































to estimate the risk of joint replacement in people without CVD as defined by the NICE 
guidelines(35), i.e., using statin as a primary prevention. 
Exclusion criteria were: invalid age or gender records; invalid joint replacement date; joint 
replacement prior to the first prescription of statin; joint replacement due to hip fracture or 
infection; revision surgery without a record of a primary joint replacement; invalid statin 
prescription data (e.g.  if the number of tablets in prescription prescribed exceeded 600 or the 
daily dose exceeded the maximum daily dose for this drug); statin-users who received a single 
statin prescription only; statin-users prescribed cerivastatin (withdrawn from the market in 
2001 due to adverse effects); and statin-users with prescription gaps of more than 90 days 
(i.e. discontinuation). 
Exposure
Exposure was defined as at least two statin prescriptions.  Prior to the first prescription, 
participants had to had at least 12 month stain-free period to prevent prevalent user bias (36). 
We prioritised UK approved statins that were available for prescription, including simvastatin, 
atorvastatin, fluvastatin, rosuvastatin, and pravastatin (simvastatin 10 mg is also available 
over-the-counter). Statins were categorised as low intensity (21-28% reduction in low-density 
lipoprotein), medium intensity (32-38%) and high intensity (42-55%) according to their lipid 
lowering potency(37) (Supplementary Table S1, available at Rheumatology online). Median 
statin intensity was calculated for each year of intake and for the total duration of statin 
exposure. 
Total duration of statin exposure was defined as the continuous use of statin, i.e., no 
discontinuation of more than 90 days between prescriptions during the follow-up period.  This 
90-day exposure window has been used in previous studies based on routinely collected data 
in primary care(29, 34, 38). 
Percentage of days covered (PDC) by statins per year was estimated as the number of 
prescriptions multiplied by days of each prescription (considering number of tablets per day or 
if not specified assuming a dosage of one tablet per day) divided by 365. Switching between 
statins or to fixed combinations was regarded as a continuation of therapy.
We accounted for overlapping tablet days assuming that the patient had finished the current 
prescription before starting the refill prescription as shown in Supplementary Figure S1, 
available at Rheumatology online (e.g. the patient was credited for the surplus statin from 
overlapping refills)(39).  
































































The primary outcome was joint replacement defined as at least one record of total or partial 
knee joint replacement (KJR) or hip joint replacement (HJR) according to the standard clinical 
terminology system used in General Practice in the United Kingdom i.e. Read codes.  Read 
codes for KJR and HJR are provided in Supplementary Material, section Total and partial joint 
replacement READ codes, available at Rheumatology online. If a person had HJR plus KJR, 
the earlier event was chosen for any joint replacement. We also examined: [1] site-specific 
(hip or knee) joint replacement; [2] joint replacement due to OA (Read codes included hip 
OA, knee OA, generalised OA, other joint OA); [3] joint replacement in people due to RA.  
OA was defined as present if at least one record of hip OA, knee OA, generalised OA, and 
OA of other joints was identified during follow-up.  
RA was defined as present if either of two definitions was met, specifically: (1) at least one 
diagnostic Read code for RA (any group) and at least one appropriate prescription of a 
DMARD with no alternative indication for the DMARD; or (2) two or more diagnostic Read 
codes for RA (on different dates) and at least one RA code in group 1 or group 2 with no 
alternative diagnosis after the final RA code (Supplementary Material, section Rheumatoid 
arthritis definition, available at Rheumatology online) (40, 41). 
Secondary outcomes: [1] joint replacement in people without CVD i.e. focusing on statin 
use for primary prevention of CVD.
Covariates
Patient demographics (e.g. age, sex, practice), comorbidities and relevant medications were 
identified as covariates. Body mass-index was not included because it caused a large number 
of missing data, especially in controls. All comorbidities, including those diagnoses used as 
alternative indications for DMARDS or alternative diagnosis for OA and peripheral joint pain, 
are defined in Supplementary Table S2, available at Rheumatology online. CVD included 
diseases of the heart and blood vessels caused by atherosclerosis including heart attack, 
myocardial infarction, coronary or ischaemic heart disease and atherosclerosis (NICE 
guidelines).

































































Each statin-user was matched with non-user by age, gender, practice, and propensity score 
(PS). We estimated a PS (i.e. probability of being prescribed statin) for each statin user and 
non-user using multivariable logistic regression. 
PS model for the main cohort included age, gender, lifestyle factors (smoking, alcohol 
dependence), RA (yes/no), RA duration in years, OA (yes/no), OA duration in years, Charlson 
comorbidity index and individual comorbidities to reduce residual confounding (diabetes 
mellitus, hypertension, cardiovascular disease, ischaemic stroke and other thromboembolic 
diseases, peripheral pain, peripheral vascular disease, atrial fibrillation, congestive heart 
disease, renal disease, valvular heart disease), and other medications used (nitrates, anti-
platelets, diuretics, β-blockers, calcium-channel blockers, angiotensin-converting enzyme 
inhibitors, angiotensin II receptor antagonists, DMARDs, oral corticosteroids).  
For the sub-cohort (Figure 1) we estimated subgroup-specific PS and re-matched 
individuals(42). PS model for peopl  without CVD at baseline included the same set of co-
variates as in the PS model for main analysis except for CVD.
PS matching was performed using the “greedy” matching algorithm(43) where a set of X cases 
was matched to a set of Y controls in a set of X decisions, excluding those who could not be 
matched. PS distribution before and after matching for the main cohort is shown in 
Supplementary Figure S2, available at Rheumatology online. Before PS matching we trimmed 
at the extreme ends of the PS tail (below the 5th and above the 95th percentile)(44). Covariate 
balance was assessed with standardised mean differences (SMD)(45). Post-matching SMD 
<0.1 indicated a good covariate balance between groups(45, 46). SMD is a validated method 
to assess whether the PS scores are comparable between exposed and unexposed groups. 
SMD is preferable over significance testing (i.e. p-value) which is influenced by sample size, 
and over the c-statistic or area under the receiver operating characteristic (ROC) curve(46). 
Time to event analysis
Cox proportional hazards regression was used to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) between statin users and non-users. For our primary analysis we 
estimated:
 Non-PS matched  HR using multivariable Cox regression, adjusting for all covariates 
including  age, gender, lifestyle factors (smoking, alcohol dependence), RA (plus 
duration in years), OA (plus duration in years), Charlson comorbidity index 
(Supplementary Table S3, available at Rheumatology online), comorbidities (diabetes 































































mellitus, hypertension, cardiovascular disease, ischaemic stroke and other 
thromboembolic diseases, peripheral pain, peripheral vascular disease, atrial 
fibrillation, congestive heart disease, renal disease, valvular heart disease), other 
medication used (nitrates, anti-platelets, diuretics, β-blockers, calcium-channel 
blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor 
antagonists, DMARDs, oral corticosteroids).  
 PS matched HR using  Cox regression  stratified on matched sets with robust standard 
errors to account for “cluster effect” within matched pairs(43, 47).
Dose-response analysis was performed using linear trends for effect of statin intensity (0 for 
non-users, 1 for low, 2 for medium and 3 for high intensity).  
In addition, competing risk of death was adjusted using the proportional sub-distribution 
hazard regression (48-50).  This was because if a person died before an outcome of interest, 
it would challenge the assessment of that outcome. 
All analyses were performed using SAS statistical software version 9.4 
Role of the Funding Source
The funding source had no role in: the design or conduct of the study; the collection, analysis, 
or interpretation of the data; or the writing of the report. The corresponding authors had full 
access to all data in the study and had final responsibility for the decision to submit the 
manuscript for publication. 
Results
Cohort description. A total of 3,981,838 individuals met our inclusion criteria, of whom 
706,943 were statins-users and 178,467 were successfully PS matched to the same number 
of non-users (PS distribution before and after matching is shown in Supplementary Figure  S2, 
available at Rheumatology online). After PS-matching, all covariates were balanced between 
the two groups (Table 1).  The number of patients at risk of having joint replacement in each 
year of follow-up is shown in Supplementary Figure S3, available at Rheumatology online. 
The mean age of the matched cohort was 62 (SD ~11, range 40-86) years and 52% were 
women (Table 1). Mean duration of follow-up was 6.88 (SD 3.98) for statin-users and 6.25 
years (SD 3.82) for non-users. The maximum period of follow up was 28 years in both groups. 
Statin prescribing. Most statin-users in the PS-matched cohort started treatment with 
medium intensity statins (73%) and had good adherence (PDC≥80) at baseline and during the 































































first year of follow-up (75% and 63% respectively). 26% of statin-users discontinued treatment 
during the first 2 years (Table 2). 
Joint replacement. In non-PS matched analysis statin-users had higher probability of having 
any joint replacement compared to non-users (HR 1.13, 95% CI 1.10 to 1.16). However, in the 
PS-matched cohort joint replacement was not associated with statins (0.99, 0.97 to 1.03)) 
(Table 3). Additional adjustment for the competing risk of death in the PS-matched cohort 
provided similar results (1.02, 0.98 to 1.05).
In the subgroup analysis, there were no relationships between statins and KJR or HJR, or joint 
replacement due to OA (Table 3). However, statin-users with RA were less likely to undergo 
joint replacement compared to non-users with RA (0.77, 0.63 to 0.94). 
Further analysis in the PS-matched cohort demonstrated an overall trend of dose response 
effect but this was only significant for any joint replacement (p for trend 0.0244) and KJR (p 
for trend 0.0210) (Figure 2, Supplementary Table S4, available at Rheumatology online).  
However, comparing to non-users, statins at the high intensity had lower risk of any joint 
replacement (HR 0.86, 95%CI 0.75 to 0.98), joint replacement due to RA (0.10, 0.02 to 0.65) 
and joint replacement due to OA (0.79, 0.68 to 0.92). 
Among people without any diagnosed CVD at baseline (i.e. primary prevention) statin-users 
had a marginally lower risk of joint replacement compared to non-users (0.96, 0.93 to 1.00). 
Discussion
The key findings of this population-based cohort study are: [1] statin use was associated with 
reduced joint replacement due to RA but not OA; [2]  high intensity statin was associated with 
reduced joint replacement due to both RA and OA; and [3] a dose response relationship was 
observed for any joint replacement and knee joint replacement outcomes. 
The main results of this study are consistent with results from four large Swedish population-
based cohorts (21) that did not find any association between statin use and joint replacement 
due to OA. We used joint replacement as the primary outcome because it is a hard outcome 
and well coded in CPRD(6).  Using this outcome without the selection of index disease (OA in 
this case) helps to avoid “index event bias”(51). We used the PS matched method to minimize  
“confounding by indication” – an important issue with observational studies examining 
therapeutic effects(52). The balanced PS between the groups suggests that confounding by 
indication was kept to the minimum according to the known factors.   The reduction of HR from 
non-PS matched to the PS-matched methods suggests that the direction of the confounding 
by indication is towards a positive (HR>1), not negative (HR<1), association. This means that 
if a positive association is observed it is likely to be biased/inflated, whereas if a negative 































































association is observed it is likely to be true and to become even more negative should this 
confounding be fully controlled. This is in line with our knowledge that both OA and RA are 
associated with CV events, hence patients with OA or RA are more likely to be given statins 
than those without these conditions. In addition, our further analysis in people without CVD 
shows that statins were negatively associated with joint replacement although it was just 
marginal (p=0.05). This suggests that the PS calculation for joint replacement outcome is 
justified and the protective effect of statin on joint replacement may be independent from CVD. 
Furthermore, we controlled for other potential biases. For example, we used the incident statin 
users in this analysis to avoid “bias of prevalent users”, as this gives a full course of the 
exposure, and to avoid left censorship or truncation (i.e., outcomes occur before baseline) that 
may be caused by using prevalence users (36, 53). If we used prevalent exposure, we were 
unable to define the starting point of the statin exposure, hence unable to measure time to 
event outcome, and unable to control “immortal time bias” by matching index dates between 
statin-users and non-users (54). 
 It is well-established that people with RA have an increased CV risk as a result of complex 
interaction between traditional risk factors (dyslipidaemia, insulin resistance, arterial 
hypertension, obesity, smoking) and chronic auto-immune inflammation (25). Statin treatment 
has been reported to reduce CV risk in RA individuals through its angio-protective, lipid-
lowering and anti-oxidative effects (24, 26). Moreover, several studies and a recent meta-
analysis of nine randomized controlled  trials report that statins may influence the inflammatory 
process and disease activity (24, 27, 28). Our findings on decreased risk of joint replacement 
due to RA in statin-users could suggest that statins reduce subsequent joint damage and slow 
the rate of progression to surgery. If statins work for both cardiovascular events and RA-
related joint replacement, this might lead to some changes in treatment recommendations.  
For example, people with RA and CVD (or at higher CV risk) could be given statins for the 
management of both conditions.  However, the small effect of statins on joint replacement due 
to RA in our study (HR=0.77, 95% CI 0.63 to 0.94) may not be clinically significant on its own 
but at this early stage we believe that a statistical significance should not be ignored. Given 
the limitations of this study, further well designed studies are still needed to examine the 
mechanism of statins in RA.  A randomised control trial to assess the efficacy and cost-
effectiveness of different treatment regimens of statin with or without other anti-rheumatic 
drugs in people with RA and cardiovascular diseases (CVDs) or high risk of CVDs is also 
justified. 
There are several potential limitations to this study. Firstly, we could only use data and 
variables that are recorded in the CPRD.  There are many variables that may influence the 
balance between statin users and non-users, hence confounding by indication cannot be fully 































































removed. For example, BMI was not included because it caused large number of missing data, 
particularly in the non-exposure group. However, after the PS matching, the two groups were 
fairly balanced for major confounding factors, suggesting a comparability between groups.  In 
addition, from the PS-matched and non PS-matched analyses, we understood the direction of 
the  unmeasured confounding, which helps us to adequately interpret the findings with 
negative association. Secondly, OA records in the CPRD reflect physician-diagnosed OA and 
are likely to follow NICE criteria for clinical OA that focus on symptomatic cases alone(55). 
Also we could not account for any delay between first symptoms and the diagnosis of OA/RA 
in primary care. This was one of the reasons why we used joint replacement as our primary 
outcomes as this is less prone to misclassification bias. Thirdly, our definition of joint 
replacement due to OA only included hip and knee OA so the results cannot be generalised 
to other joints affected by OA. Fourthly, cholesterol testing is not routine in the UK general 
practice, therefore serum cholesterol was not included in the propensity score model. Fifthly, 
we did not consider variation in statin prescriptions during follow-up, but used a simple 
continuous measure (no gaps more than 90 days) that may lead to potential imbalance in 
terms of exposure between statin users and non-users. Moreover, users of high intensity 
statins particularly in the RA-group were underrepresented in our analysis (Supplementary 
Table S4, available at Rheumatology online) and therefore, a well-designed study with 
balanced groups is needed to confirm observed dose-response effect
Conclusion
In summary, statins may reduce the risk of joint replacement, especially when given at high 
strength and in people with RA. The evidence in knee replacement is stronger than that in hip 
replacement. Further studies to investigate mechanisms of statin and its clinical impact in 
people with RA are warranted.









































































Index year, n (%)

















Age in years, mean (SD) 63.03 (11.02) 63.42 (11.11) 0.036 61.91 (10.64) 62.00 (11.74) 0.007















Alcohol dependence, n (%) 522 (0.09) 538 (0.10) 149 (0.08) 232 (0.13)
RA, n (%) 5,702 (1.01) 4,493 (0.80) 0.023 1,906 (1.07) 2,036 (1.14) 0.007
Duration (years), mean (SD) 0.09 (1.12) 0.07 (1.00) 0.074 0.09 (1.13) 0.10 (1.21) 0.025
Any OA, n (%) 97,800 (17.39) 74,482 (13.24) 0.115 28,387 
(15.91)
30,626 (17.16) 0.034
Duration (years), mean (SD) 1.24 (3.66) 0.97 (3.35) 0.077 1.12 (3.50) 1.19 (3.59) 0.019
Comorbidities







Charlson Index, mean (SD) 0.89 (1.82) 0.76 (1.79) 0.074 0.80 (1.77) 0.85 (1.83) 0.025
Renal, n (%) 31,627 (5.62) 15,139 (2.69) 0.147 8,582 (4.81) 8,302 (4.65) 0.007
Coronary, n (%) 123,781 
(22.00)
15,376 (2.73) 0.612 7,576 (4.25) 6,907 (3.87) 0.019
Cerebrovascular disease, n 
(%)
48,903 (8.69) 9 291 (1.65) 0.322 5,297 (2.97) 4,230 (2.37) 0.037
Peripheral vascular disease, 
n (%)
23,586 (4.19) 4,908 (0.87) 0.213 2,838 (1.59) 2,295 (1.29) 0.026
Carotid, n (%) 2,106 (0.37) 210 (0.04) 0.074 107 (0.06) 55 (0.03) 0.014
Atrial fibrillation, n (%) 27,506 (4.89) 13,601 (2.42) 0.132 7,012 (3.93) 6,726 (3.77) 0.008
Valvular heart disease, n 
(%)
1,439 (0.26) 624 (0.11) 0.034 364 (0.20) 350 (0.20) 0.002








Without complications 101,978 
(18.13)
10,083 (1.79) 0.666 4,325 (2.42) 2,785 (1.56) 0.093
With complications 16,876 (3.00) 2,308 (0.41) 1,474 (0.83) 778 (0.44) 
Congestive heart disease, n 
(%) 
17,539 (3.12) 6,294 (1.12) 0.139 3,112 (1.74) 2,576 (1.44) 0.024
Medication use (n (%))
Nitrates 87,410 (15.54) 6,441 (1.15) 0.539 2,645 (1.48) 1,895 (1.06) 0.038
Diuretics 182,956 
(32.52)





35,241 (6.26) 0.955 19,129 
(10.72)
16,214 (9.09) 0.055





43,265 (7.69) 0.721 28,112 
(15.75)
27,586 (15.46) 0.008
AGT antagonists 52,939 (9.41) 16,843 (2.99) 0.268 11,386 (6.38) 11,378 (6.38) 0.001
Β-blockers 170,622 
(30.33)
42,830 (7.61) 0.479 25,180 
(14.11)
27,614 (15.47) 0.038
Note: PS – propensity score, SMD – standardised mean difference, SD – standard deviation, DMARDs – disease-modifying 
antirheumatic drugs, AGT antagonists - angiotensin II receptor antagonists.































































Table 2. Statins characteristics. 
Variable Measure
N 178,467




Total exposure period, days, mean (SD) 2,024 (1566)
Total exposure period, years, n (%)
Less than 2 years 46,664 (26.15)
3-4 years 30,679 (17.19)
5-6 years 27,407 (15.36)
7-8 years 23,744 (13.30)
9-10 years 19,587 (10.98)
>10 years 30,386 (17.03)
Baseline PDC, mean (SD) 0.85 (0.24)
Baseline PDC >=80%, n (%) 133,664 (74.90)
Year 1 PDC (>2 years intake), mean (SD) 0.76 (0.25)
Year 1 PDC>=80% (>2 years intake), n (%) 88,700 (62.48)
Note: SD – standard deviation, PDC – proportion of days covered. 



















Statin-users 21,430 3,989,753 7.09 (4.07) 1.13 (1.10 to 1.16) 6,490 1,229,427 6.88 (3.98) 0.99 (0.97 to 1.03)
Non-users 15,910 3,607,011 6.41 (3.90) 1 (reference) 5,691 1,115,447 6.25 (3.82) 1 (reference)
Joint replacement due to OA
Statin-users 16,263 4,013,272 7.14 (4.08) 1.11 (1.08 to 1.15) 4,901 1,236,347 6.92 (3.99) 0.97 (0.94 to 1.01)
Non-users 11,821 3,623,933 6.44 (3.91) 1 (reference) 4,378 1,120,856 6.28 (3.83) 1 (reference)
Joint replacement due to RA
Statin-users 549 4,086,522 7.27 (4.12) 0.90 (0.77 to 1.05) 173 1,256,995 7.04 (4.03) 0.77 (0.63 to 0.94)
Non-users 431 3,674,882 6.53 (3.95) 1 (reference) 191 1,139,272 6.39 (3.88) 1 (reference)
Hip joint replacement
Statin-users 9,894 4,044,099 7.19 (4.10) 1.08 (1.05 to 1.13) 3,104 1,244,379 6.97 (4.01) 0.98 (0.93 to 1.03)
Non-users 8,265 3,641,043 6.47 (3.92) 1 (reference) 2,783 1,128,209 6.32 (3.85) 1 (reference)
Knee joint 
replacement
Statin-users 12,444 4,031,130 7.17 (4.09) 1.17 (1.13 to 1.21) 3,675 1,241,714 6.95 (3.99) 1.00 (0.96 to 1.05)
Non-users 8,350 3,640,147 6.47 (3.92) 1 (reference) 3,165 1,126,343 6.31 (3.85) 1 (reference)
Note: PS – propensity score, JR – joint replacement, OA – osteoarthritis, RA – rheumatoid arthritis, SD- standard deviation, 
hazard ratios (HR) with 95% confidence intervals (CI)
* - Multivariate Cox regression model adjusted for covariates included in the PS-model (age, gender, smoking, alcohol 
consumption, RA (plus duration in years), OA (plus duration in years), Charlson comorbidity index, comorbidities (diabetes 
mellitus, hypertension, cardiovascular disease, ischaemic stroke and other thromboembolic diseases, peripheral pain, 
peripheral vascular disease, atrial fibrillation, congestive heart disease, renal disease, valvular heart disease), other medication 
used (nitrates, antiplatelets, diuretics, β-blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors, 
angiotensin II receptor antagonists, DMARDs, oral corticosteroids)
** - Cox regression model stratified on PS matched sets with robust standard errors to account for “cluster effect” and 
subpopulation differences































































Figure 1. Flow chart of cohort 
Figure 2. Statin use and joint replacement surgery: dose-response analysis
Dose-response analysis was performed using Cox regression and compared people taking low, 
medium and high intensity statins with non-users (reference category). Statin exposure was 
categorised as low (21-28% reduction in low-density lipoprotein cholesterol), medium (32-38%) and 
high (42-55%) intensity.
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Figure 1. Flow chart of cohort 
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Figure 2. Statin use and joint replacement surgery: dose-response analysis. Note: Dose-response analysis 
was performed using Cox regression and compared people taking low, medium and high intensity statins 
with non-users (reference category). Statin exposure was categorised as low (21-28% reduction in low-
density lipoprotein cholesterol), medium (32-38%) and high (42-55%) intensity. 
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Supplementary Table S1. Statin intensity groups1
Category Drug name and dose
Low-intensity statins: 
(21–29% reduction in LDL cholesterol)
 fluvastatin 20 mg per day and 40 mg per day
 pravastatin 10 mg per day, 20 mg per day, and  
40 mg per day
 simvastatin 10 mg per day.
Medium-intensity statins: 
(32–38% reduction in LDL cholesterol)
 fluvastatin 80 mg per day
 simvastatin 20 mg per day and 40 mg per day
 atorvastatin 10 mg per day
 rosuvastatin 5 mg per day.
High-intensity statins: 
(42–55% reduction in LDL cholesterol)
 simvastatin 80 mg per day
 atorvastatin 20 mg per day, 40 mg per day and 
80 mg per day
 rosuvastatin 10 mg per day, 20 mg per day and 
40 mg per day.
LDL: low-density lipoprotein.






























































Total and partial joint replacement READ codes
Total hip replacement
Medcode Read code Description
394 7K22z00 Total prosthetic replacement of hip joint NOS
589 7K21.17 THR - Total prosthetic replacement hip joint without cement
2224 7K20.1G THR - Total prosthetic replacement of hip joint using cement
2734 7K22.12 THR - Other total prosthetic replacement of hip joint
5481 7K20.00 Total prosthetic replacement of hip joint using cement
6013 7K20.1C Muller total replacement of hip joint using cement
9762 7K22.00 Other total prosthetic replacement of hip joint
10341 7K21y00 Total prosthetic replacement hip joint not using cement OS
10348 7K20300 Primary hybrid total replacement of hip joint NEC
10856 7K20000 Primary cemented total hip replacement
16671 7K20.13 Charnley total replacement of hip joint using cement
18442 7K21.00 Total prosthetic replacement of hip joint not using cement
28468 7K20.14 Exeter total replacement of hip joint using cement
29977 7K20.1E Stanmore total replacement of hip joint using cement
33439 7K22000 Primary total prosthetic replacement of hip joint NEC
34997 7K20.1A McKee total replacement of hip joint using cement
36590 7K20.18 Howse total replacement of hip joint using cement
37631 7K22y00 Other specified total prosthetic replacement of hip joint
38001 7K20y00 Total prosthetic replacement of hip joint using cement OS
38332 7K20.17 Furlong total replacement of hip joint using cement
38347 7K21z00 Total prosthetic replacement hip joint not using cement NOS
47483 7K21000 Primary uncemented total hip replacement
47715 7K20.1B Monk total replacement of hip joint using cement
47735 7K21.12 Furlong total replacement of hip joint not using cement
47812 7K20z00 Total prosthetic replacement of hip joint using cement NOS
51519 7K21.15 Monk total replacement of hip joint not using cement
52714 7K20011 Charnley cemented total hip replacement
52901 7K20.16 Freeman total replacement of hip joint using cement
53109 7K21.11 Freeman total replacement of hip joint not using cement
55207 7K22011 Primary hybrid total replacement of hip joint NEC
56215 7K20.19 Ilch total replacement of hip joint using cement
62092 7K20.1F Turner total replacement of hip joint using cement
66139 7K20.15 Farrer total replacement of hip joint using cement
71351 7K20.12 Aufranc total replacement of hip joint using cement
73951 7K21.16 Ring total replacement of hip joint not using cement






























































94273 7K20.1D Pretoria total replacement of hip joint using cement
96435 7K21.13 Lord total replacement of hip joint not using cement
Hip replacement not specified as total (including hemiarthroplasty)
Medcode Read code Description
47483 7K21000 Primary uncemented total hip replacement
17860 7K20.11 Arthroplasty of hip joint using cement
88885 7K6e.00 Hybrid prosthetic replacement of hip joint using cement
88986 7K6d.00 Hybrid prosthetic replace hip joint cemented femoral compon
90609 7K6c.00 Hybrid prosthetic replacement hip joint cemented acetab comp
90708 7K6e000 Primary hybrid prosthetic replacement hip joint cement NEC
102322 14N3100 H/O hip replacement
104563 7K6ez00 Hybrid prosthetic replacement of hip joint using cement NOS
105065 7K6d000 Primary hybrid prosthetic replace hip jo cemented femo comp
106599 8AC..00 Metal-on-metal hip replacement annual review
107679 7K6dy00 OS hybrid prosthetic replacement hip jo cement femoral comp
108058 7K6ey00 OS hybrid prosthetic replacement of hip joint using cement
111415 7K6dz00 Hybrid prosthetic replace hip jo cemented femoral compon NOS
10011 7K22.11 Other arthroplasty of hip joint
17615 7K68500 Excision arthroplasty of hip
100059 7L0G211 Colonna arthroplasty of hip
106896 ZV45R00 [V]Metal-on-metal hip prosthesis in situ
16894 ZV43612 [V]Has artificial hip joint
17615 7K68500 Excision arthroplasty of hip
2226 7K23z00 Prosthetic cemented hemiarthroplasty of hip NOS
6681 7K23.12 Austin - Moore hemiarthroplasty of hip joint using cement
9739 7K24.19 Thompson hemiarthroplasty of hip joint not using cement
12287 7K24.12 Austin Moore hemiarthroplasty of hip joint not using cement
12847 7K23.00 Prosthetic cemented hemiarthroplasty of hip
15049 7K25y00 Other specified other prosthetic hemiarthroplasty of hip
18004 7K23.16 Thompson hemiarthroplasty of hip joint using cement
21366 7K24.13 Bateman hemiarthroplasty of hip joint not using cement
27448 7K25z00 Other prosthetic hemiarthroplasty of hip NOS
28808 7K25000 Primary prosthetic hemiarthroplasty of hip NEC
29573 7K25.00 Other prosthetic hemiarthroplasty of hip
31930 7K23100 Conversion to cemented hemiarthroplasty of hip
34383 7K24z00 Prosthetic uncemented hemiarthroplasty of hip NOS
41116 7K23000 Primary cemented hemiarthroplasty of hip
41489 7K24100 Conversion to uncemented hemiarthroplasty of hip
43460 7K24.00 Prosthetic uncemented hemiarthroplasty of hip






























































43789 7K23x00 Conversion from cemented hemiarthroplasty of hip
47482 7K24000 Primary uncemented hemiarthroplasty of hip
48955 7K23.13 Hastings hemiarthroplasty of hip joint using cement
50091 7K24.18 Austin Moore hemiarthroplasty of hip joint not using cement
59936 7K23y00 Other specified prosthetic cemented hemiarthroplasty of hip
61099 7K23.14 Monk hemiarthroplasty of hip joint using cement
62046 7K24y00 Other specified prosthetic uncemented hemiarthroplasty hip
62249 7K24.17 Monk hemiarthroplasty of hip joint not using cement
65481 7K25100 Conversion to prosthetic hemiarthroplasty of hip NEC
67352 7K25x00 Conversion from previous hemiarthroplasty of hip NEC
71947 7K24x00 Conversion from uncemented hemiarthroplasty of hip
96760 7K24.14 Brown hemiarthroplasty of hip joint not using cement
111852 7K24.15 Judet hemiarthroplasty of hip joint not using cement
Total knee replacement
Medcode Read code Description
673 7K32z00 Other total prosthetic replacement of knee joint NOS
3414 7K30.00 Total prosthetic replacement of knee joint using cement
3973 7K32.12 TKR - Other total prosthetic replacement of knee joint
5362 7K30.1V TKR -Total prosthetic replacement of knee joint using cement
8006 7K30z00 Total prosthetic replacement of knee joint using cement NOS
8555 7K32.00 Other total prosthetic replacement of knee joint
9877 7K31.12 TKR - Total prosthetic replacement knee joint without cement
10372 7K30y00 Total prosthetic replacement of knee joint using cement OS
17471 7K31.00 Total prosthetic replacement of knee joint not using cement
20746 7K30000 Primary cemented total knee replacement
28048 7K32000 Primary total knee replacement NEC
37979 7K32y00 Other total prosthetic replacement of knee joint OS
44775 7K30.18 Denham total replacement of knee joint using cement
44926 7K30.1R Stanmore total replacement of knee joint using cement
46475 7K30.16 Charnley total replacement of knee joint using cement
47301 7K30.1N Polycentric total replacement of knee joint using cement
49053 7K31000 Primary uncemented total knee replacement
49716 7K30.1S Swanson total replacement of knee joint using cement
49813 7K30.17 Deane total replacement of knee joint using cement
50829 7K31y00 Total prosthetic replacement knee joint not using cement OS
54860 7K30.19 Freeman total replacement of knee joint using cement
55991 7K30.1P Sheehan total replacement of knee joint using cement
58612 7K31z00 Total prosthetic replacement knee joint not using cement NOS
61687 7K30.13 Attenborough total replacement of knee joint using cement






























































63086 7K30.1T Uci total replacement of knee joint using cement
63802 7K30.1A Geomedic total replacement of knee joint using cement
66707 7K30.1E Herbert total replacement of knee joint using cement
70507 7K30.1Q Shiers total replacement of knee joint using cement
71456 7K30.15 Cavendish total replacement of knee joint using cement
83544 7K32011 Primary hybrid total knee replacement NEC
92246 7K30.1H Liverpool total replacement of knee joint using cement
93344 7K30.11 Anametric total replacement of knee joint using cement
99912 7K30.1I Manchester total replacement of knee joint using cement
101522 7K30.1F Ilch total replacement of knee joint using cement
108493 7K30.1J Marmor total replacement of knee joint using cement
Knee replacement not specified as total (including hemiarthroplasty)
Medcode Read code Description
102279 14N3200 H/O knee replacement
106130 7K6q000 Primar hybrid prosthetic replacement knee joint using cement
108352 7K6qy00 OS hybrid prosthetic replacement of knee joint using cement
109799 7K6q.00 Hybrid prosthetic replacement of knee joint using cement
111558 7K30.1C Guepar hinge replacement of knee joint using cement
10406 7K32.11 Other arthroplasty of knee joint
31977 7K30.12 Arthroplasty of knee joint using cement
47764 7K31.11 Arthroplasty of knee joint not using cement
101810 7K30.1U Wallidus hinge arthroplasty of knee joint using cement
103334 7K30.14 Autophor arthroplasty of knee joint using cement
9817 7K38.00 Uncemented unicompartmental knee replacement
11225 7K37.00 Cemented unicompartmental knee replacement
36343 7K37000 Primary cemented unicompartmental knee replacement
37950 7K39000 Primary hybrid unicompartmental knee replacement
54343 7K38000 Primary uncemented unicompartmental knee replacement
55470 7K39.00 Hybrid unicompartmental knee replacement
94310 7K3A.00 Unicompartmental knee replacement NOS































































Rheumatoid artritis (RA)  was defined using an algorithm proposed by 35 and adapted for use in the CPRD 
by 36. Individuals were categorized according to the highest RA group in their CPRD record. All drugs 
licensed for the treatment of RA in the UK including conventional and biological disease modifying anti-
rheumatic drugs (DMARDs) were selected according to the British National Formulary (BNF) at the time 
of the study (December 2017) (please see below).  A list of potential alternative indications for DMARDs 
was compiled from the BNF and included: psoriasis and psoriatic arthritis, ankylosing spondylitis and other 
spondyloarthropathies, juvenile idiopathic arthritis, inflammatory bowel disease, systemic lupus 
erythematosus (SLE), transplants, vasculitis, leukaemia, lymphoma. Alternative diagnoses to RA (i.e., those 
which if present after the final RA code in the record would supersede a diagnosis of RA), were: psoriatic 
arthritis, ankylosing spondylitis and other spondyloarthropathies.  
All drugs licensed for the treatment of RA in the UK including conventional and biological disease 
modifying anti-rheumatic drugs (DMARDs) were selected according to the British National Formulary 















































































































Psoriasis + + +
Psoriatic arthritis + +
Ankylosing and other 
seronegative spondylitis
+ + +








Systemic vasculitis + +
Leukaemia and lymphomas +
Septic and other 
inflammatory arthritis (inc 




Rheumatoid arthritis (inc 




Mixed connective tissue 
















Chronic pulmonary disease +
Congestive heart disease + +
Dementia +
Diabetes (inc diabetes with 
complications)
+ +






























































Peripheral joint pain affecting knee, hip and other joints in people over age of 40 was defined 
as pain in peripheral joint in the absence of a record of another specific non-OA diagnosis 
(rheumatic disease, soft-tissue disorders, other bone/cartilage diseases)  53.  
Smoking status was categorised as never smoked, current smoker and ex-smoker 54. 
Alcohol dependence was recorded as absent or present using a list of Read codes provided by 
Thompson et al. 55 (all codes were updated using current code list).
The Charlson comorbidity index was calculated using Read/OXMIS codes list adapted for use 
in CPRD 56 that includes 17 comorbid diseases with corresponding weighted index 57,58 Appendix 
5. 
CVD included diseases of the heart and blood vessels caused by the process of atherosclerosis 
including heart attack, myocardial infarction, coronary or ischaemic heart disease, atherosclerosis 
(NICE guidelines 59).
Hemiplegia +




Peptic ulcer disease +
Peripheral vascular disease +







Pyogenic arthritis and 



































































Supplementary Table S3 Weighted index of comorbidity updated by (Quan et al, 2010) 
AIDS: acquired immunodeficiency syndrome;  The following comorbid conditions were mutually exclusive: 
diabetes with chronic complications and diabetes without chronic complications; mild liver disease and 
moderate or severe liver disease; and any malignancy and metastatic solid tumour.
Conditions Updated weight
Myocardial infarction 0
Congestive heart disease 2
Peripheral vascular disease 0
Cerebrovascular disease 0
Dementia 2
Chronic pulmonary disease 1
Rheumatological disease 1
Peptic ulcer disease 0
Hemiplegia and paraplegia 2
Renal disease 1




Cancer or  Leukaemia or  Lymphoma 2
Liver disease                        mild 2



































































Supplementary Table S4 Dose-response analysis




HR (95%CI)* p-value for trend
Any joint replacement
Non-users 178467 5691 6.25 (3.82) 1 0.0244
Low 32652 1571 8.54 (4.77) 1.05 (0.98 to 1.13)
Medium 130980 4517 6.58 (3.59) 0.99 (0.96 to 1.04)
High 14835 402 5.90 (4.34) 0.86 (0.75 to 0.98)
Joint replacement due to OA
Non-users 40721 4378 6.63 (3.93) 1 0.0674
Low 8501 1213 9.14 (4.86) 1.02 (0.94 to 1.11)
Medium 29760 3387 7.00 (3.70) 0.98 (0.94 to 1.03)
High 3111 301 6.61 (4.44) 0.79 (0.68 to 0.92)
Joint replacement due to RA
Non-users 2746 191 6.51 (3.87) 1 0.4190
Low 469 38 8.83 (4.65) 0.66 (0.43 to 1.00)
Medium 1940 126 6.85 (3.73) 0.91 (0.72 to 1.14)
High 226 9 6.21 (4.71) 0.10 (0.02 to 0.65)
Hip joint replacement
Non-users 175684 2783 6.32 (3.85) 1 0.1173
Low 31905 747 8.67 (4.80) 1.08 (0.97 to 1.20)
Medium 128826 2154 6.66 (3.61) 0.96 (0.91 to 1.01)
High 14632 203 5.96 (4.37) 0.90 (0.75 to 1.08)
Knee joint replacement
Non-users 175 302 3165 6.31 (3.85) 1 0.0210
Low 31735 917 8.64 (4.78) 1.06 (0.96 to 1.16)
Medium 128434 2546 6.64 (3.61) 1.01 (0.95 to 1.06)
High 14623 212 5.96 (4.37) 0.79 (0.66 to 0.95)
in bold – HR<1.0.
Supplementary figure legend
Supplementary Figure S1. Prescription fill pattern before and after adjustment. 
Supplementary Figure S2. Distribution of Propensity Score before and after matching A) 
Distribution of Propensity Score before matching; B) Distribution of Propensity Score after matching
Supplementary Figure S3. Number of patients at risk of having joint replacements in each year of 
follow-up




























































































































































































































































Page 33 of 33 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
